Yutao Gong

2.2k total citations · 1 hit paper
35 papers, 1.1k citations indexed

About

Yutao Gong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yutao Gong has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Yutao Gong's work include Cancer Genomics and Diagnostics (7 papers), Economic and Financial Impacts of Cancer (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Yutao Gong is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Economic and Financial Impacts of Cancer (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Yutao Gong collaborates with scholars based in United States, China and Israel. Yutao Gong's co-authors include Richard Pazdur, Gideon M. Blumenthal, Patricia Keegan, Julia A. Beaver, Ian C. Olson, Fred H. Wilt, Christopher E. Killian, Benjamin Gilbert, Dickran Kazandjian and Liam J. Holt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Advanced Functional Materials.

In The Last Decade

Yutao Gong

30 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trends in the approval of cancer therapies by the FDA in the twenty-first century

2023 155 citations Emma Scott, Andrea Baines et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yutao Gong United States	12	447	267	255	175	126	35	1.1k
Huawei Cai China	25	267 0.6×	163 0.6×	152 0.6×	457 2.6×	287 2.3×	101	1.7k
Francesco Sassi Italy	29	570 1.3×	315 1.2×	481 1.9×	534 3.1×	80 0.6×	84	3.1k
Yoseph Addadi Israel	20	242 0.5×	69 0.3×	192 0.8×	488 2.8×	169 1.3×	43	1.2k
Jeroen Goos Netherlands	16	173 0.4×	114 0.4×	839 3.3×	390 2.2×	607 4.8×	32	1.8k
Michael B. Duncan United States	17	208 0.5×	108 0.4×	47 0.2×	697 4.0×	36 0.3×	22	1.5k
Vassilis Koutoulidis Greece	19	222 0.5×	169 0.6×	55 0.2×	119 0.7×	86 0.7×	78	1.1k
Zhiyi Zhou China	27	149 0.3×	92 0.3×	271 1.1×	662 3.8×	582 4.6×	82	2.1k
A.A. Mulder-Stapel Netherlands	16	294 0.7×	66 0.2×	59 0.2×	257 1.5×	19 0.2×	20	796
Jürgen Hofmann Switzerland	14	112 0.3×	109 0.4×	39 0.2×	159 0.9×	130 1.0×	53	745
Naoto Kondo Japan	23	586 1.3×	294 1.1×	55 0.2×	579 3.3×	121 1.0×	126	2.2k

Countries citing papers authored by Yutao Gong

Since Specialization

Citations

This map shows the geographic impact of Yutao Gong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yutao Gong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yutao Gong more than expected).

Fields of papers citing papers by Yutao Gong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yutao Gong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yutao Gong. The network helps show where Yutao Gong may publish in the future.

Co-authorship network of co-authors of Yutao Gong

This figure shows the co-authorship network connecting the top 25 collaborators of Yutao Gong. A scholar is included among the top collaborators of Yutao Gong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yutao Gong. Yutao Gong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fan, Jiaxin, et al.. (2026). An FDA analysis of the association of tumor growth rate, overall survival, and progression-free survival in patients with metastatic non-small cell lung cancer. The Oncologist. 31(3).

Huang, Xiaoping, Ruyi Zhang, Yutao Gong, et al.. (2023). Selective solvent extraction of Cu(II) from aqueous solutions using an acyl-based thiourea: Extraction study and DFT analysis of reaction mechanism. Hydrometallurgy. 223. 106226–106226. 4 indexed citations

Huang, Kaihua, Chengke Wang, Yutao Gong, et al.. (2023). Adsorption kinetic studies of octyl hydroxamic acid on galena surface. Minerals Engineering. 198. 108101–108101. 8 indexed citations

Scott, Emma, Andrea Baines, Yutao Gong, et al.. (2023). Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nature Reviews Drug Discovery. 22(8). 625–640. 155 indexed citations breakdown →

Schneider, Julie A., Yutao Gong, Kirsten B. Goldberg, et al.. (2021). The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology. Clinical Cancer Research. 27(19). 5161–5167. 1 indexed citations

Mason, Jeremy, Yutao Gong, Laleh Amiri‐Kordestani, et al.. (2021). Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. JCO Clinical Cancer Informatics. 5(5). 758–767. 2 indexed citations

Liu, Qi, Feng Ge, Yaning Wang, et al.. (2020). A novel approach for personalized response model: deep learning with individual dropout feature ranking. Journal of Pharmacokinetics and Pharmacodynamics. 48(1). 165–179. 6 indexed citations

Scott, Emma, Yutao Gong, Ashim Subedee, et al.. (2020). Emerging oncology drug targets in the 21st century: An FDA analysis.. Journal of Clinical Oncology. 38(15_suppl). e14067–e14067.

Liu, Qi, Chenan Zhang, Yutao Gong, et al.. (2020). Abstract CT086: Pneumonitis incidence in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy in clinical trials and real-world data. Cancer Research. 80(16_Supplement). CT086–CT086. 2 indexed citations

10.

Bonomi, P., Meredith K. Chuk, Alexander I. Spira, et al.. (2020). Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer. Therapeutic Innovation & Regulatory Science. 54(5). 1208–1214. 2 indexed citations

11.

Chang, Elaine, Chana Weinstock, Lijun Zhang, et al.. (2020). FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 27(4). 922–927. 135 indexed citations

12.

Chang, Elaine, Yutao Gong, Chana Weinstock, et al.. (2020). Consistency of patient versus investigator reporting of symptomatic adverse events (AEs) in international trials.. Journal of Clinical Oncology. 38(6_suppl). 38–38. 1 indexed citations

13.

Mason, Jeremy, Yutao Gong, Laleh Amiri‐Kordestani, et al.. (2020). Abstract PD2-07: Prediction of CDK inhibitor efficacy in ER+/HER2- breast cancer using machine learning algorithms. Cancer Research. 80(4_Supplement). PD2–7.

14.

Menefee, Michael E., Yutao Gong, Pallavi S. Mishra‐Kalyani, et al.. (2019). Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials.. Journal of Clinical Oncology. 37(15_suppl). 9105–9105. 4 indexed citations

15.

Kanapuru, Bindu, Yutao Gong, Pallavi S. Mishra‐Kalyani, et al.. (2019). Project Switch: Lenalidomide and dexamethasone (Len-Dex) as a potential synthetic control arm (SCA) in relapsed or refractory multiple myeloma (rrMM).. Journal of Clinical Oncology. 37(15_suppl). 8047–8047. 2 indexed citations

16.

He, Yanyan, M. Yousuff Hussaini, Yutao Gong, & Ying Xiao. (2016). Optimal unified combination rule in application of Dempster‐Shafer theory to lung cancer radiotherapy dose response outcome analysis. Journal of Applied Clinical Medical Physics. 17(1). 4–11.

17.

Gong, Yutao, Jialu Yu, Dalong Pang, et al.. (2016). Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance. Frontiers in Oncology. 6. 47–47. 4 indexed citations

18.

Giaddui, T, Wenzhou Chen, Jialu Yu, et al.. (2016). Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiation Oncology. 11(1). 66–66. 79 indexed citations

19.

Gong, Yutao, Christopher E. Killian, Ian C. Olson, et al.. (2012). Phase transitions in biogenic amorphous calcium carbonate. Proceedings of the National Academy of Sciences. 109(16). 6088–6093. 244 indexed citations

20.

Killian, Christopher E., Rebecca A. Metzler, Yutao Gong, et al.. (2011). Self‐Sharpening Teeth: Self‐Sharpening Mechanism of the Sea Urchin Tooth (Adv. Funct. Mater. 4/2011). Advanced Functional Materials. 21(4). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact